Loading
Latest filing published 26 May 2022 for Antares Pharma, INC., €9.8M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Robert F. Apple in Antares Pharma, Inc., where the filings describe the role as chief executive. Over a trading history stretching from 8 June 2021 to 24 May 2022, the count stands at 5 filings.
Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
On 26 May 2022 came the latest disclosure, a transaction for €9.8M in Antares Pharma, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations